Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating income | $39.0M | -$33.6M | -$52.2M | -$61.2M | -$39.9M | -$22.3M | -$211M |
| Net income | -$36.5M | -$34.8M | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$210M |
| EPS (diluted) | -$161.82 | -$7.62 | -$2.05 | -$2.43 | -$36.08 | -$18.53 | $3.98 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.3M | -$38.2M | -$52.3M | -$42.9M | -$36.9M | -$18.6M | -$6.73M |
| Capital expenditures | — | — | $223K | $196K | — | — | — |
| Free cash flow | — | — | -$52.5M | -$43.1M | — | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11.3M | $164M | $62.6M | $32.8M | $21.5M | $14.2M | $258M |
| Total assets | $56.6M | $172M | $122M | $73.2M | $38.2M | $17.1M | $261M |
| Total liabilities | $8.14M | $6.11M | $4.99M | $11.4M | $5.90M | $1.30M | $20.1M |
| Shareholders' equity | -$71.1M | $165M | $117M | $61.8M | $32.3M | $15.8M | $240M |
| Retained earnings | -$69.5M | -$104M | -$156M | -$218M | -$256M | -$278M | -$487M |
| Shares (wtd avg diluted) | 260K | 25.3M | 25.3M | 25.4M | 1.06M | 1.16M | 1.36M |
Every figure is extracted from Damora Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.